Russian Move To Limit Medtech Imports Could Harm Domestic Innovation
This article was originally published in Clinica
Executive Summary
Import substitution and tendering practices that put non-Russian/EAEU-based medtech manufacturers at a disadvantage were introduced under Russian Resolution 102 in February 2015. Clinica asked executives from IMEDA, Russia’s International Medical Device Manufacturers Association, what effect this will have on market supply, patient care and innovation
You may also be interested in...
Russia's Medtech Looks For Chain Reaction After Philips Partnership Deal
Russia's health care sector has been under strain, suffering budgets cuts and repercussions from the ongoing sanctions. In the midst of this, plans to reinforce the local medtech industry received a boost recently when global top 10 manufacturer Philips Healthcare committed funds to embarking on new R&D locally and to further partnerships in Russia.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.
Swiss-EU Standoff Set To End? Medtechs Eye MRA Action
Negotiations aimed at renewing the close trading relationship and barrier-free mutual market access between Switzerland and the EU got underway on 19 March. Swiss medtech companies welcomed the move, stressing the need for the defunct mutual recognition agreement to be updated.